title: Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation.
abstract: Steroid receptor coactivator-3 (SRC-3) is a histone acetyltransferase and nuclear hormone receptor coactivator, located on 20q12, which is amplified in several epithelial cancers and well studied in breast cancer. However, its possible role in lung cancer pathogenesis is unknown. We found SRC-3 to be overexpressed in 27% of non-small cell lung cancer (NSCLC) patients (n = 311) by immunohistochemistry, which correlated with poor disease-free (P = 0.0015) and overall (P = 0.0008) survival. Twenty-seven percent of NSCLCs exhibited SRC-3 gene amplification, and we found that lung cancer cell lines expressed higher levels of SRC-3 than did immortalized human bronchial epithelial cells (HBEC), which in turn expressed higher levels of SRC-3 than did cultured primary human HBECs. Small interfering RNA-mediated downregulation of SRC-3 in high-expressing, but not in low-expressing, lung cancer cells significantly inhibited tumor cell growth and induced apoptosis. Finally, we found that SRC-3 expression is inversely correlated with gefitinib sensitivity and that SRC-3 knockdown results in epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancers becoming more sensitive to gefitinib. Taken together, these data suggest that SRC-3 may be an important oncogene and therapeutic target for lung cancer.
authors.affiliation: Division of Translational Research, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
authors.forename: Di
authors.initials: D
authors.lastname: Cai
authors.forename: David S
authors.initials: DS
authors.lastname: Shames
authors.forename: Maria Gabriela
authors.initials: MG
authors.lastname: Raso
authors.forename: Yang
authors.initials: Y
authors.lastname: Xie
authors.forename: Young H
authors.initials: YH
authors.lastname: Kim
authors.forename: Jonathan R
authors.initials: JR
authors.lastname: Pollack
authors.forename: Luc
authors.initials: L
authors.lastname: Girard
authors.forename: James P
authors.initials: JP
authors.lastname: Sullivan
authors.forename: Boning
authors.initials: B
authors.lastname: Gao
authors.forename: Michael
authors.initials: M
authors.lastname: Peyton
authors.forename: Meera
authors.initials: M
authors.lastname: Nanjundan
authors.forename: Lauren
authors.initials: L
authors.lastname: Byers
authors.forename: John
authors.initials: J
authors.lastname: Heymach
authors.forename: Gordon
authors.initials: G
authors.lastname: Mills
authors.forename: Adi F
authors.initials: AF
authors.lastname: Gazdar
authors.forename: Ignacio
authors.initials: I
authors.lastname: Wistuba
authors.forename: Thomas
authors.initials: T
authors.lastname: Kodadek
authors.forename: John D
authors.initials: JD
authors.lastname: Minna
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics / Q000473:pathology*; D048708:Cell Growth Processes / Q000502:physiology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000502:physiology; D000068818:Cetuximab; D018572:Disease-Free Survival; D004357:Drug Synergism; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism; D000077156:Gefitinib; D018628:Gene Dosage; D055785:Gene Knockdown Techniques; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics / Q000473:pathology*; D056921:Nuclear Receptor Coactivator 3 / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011799:Quinazolines / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D015398:Signal Transduction
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D012333:RNA, Messenger; C538866:NCOA3 protein, human; D056921:Nuclear Receptor Coactivator 3; D066246:ErbB Receptors; D000068818:Cetuximab; D000077156:Gefitinib